Condition: Sickle Cell Disease · Thalassaemia · Congenital Dyserythropoietic Anemia (CDA) · Sponsor: Hospital Universitari Vall d'Hebron Research Institute
INTEGRA aims at enabling personalized medicine for RHADs patients by the establishment of an integrative diagnostic approach based on deep phenotypic and genetic characterization through combining new generation methodologies.
This description comes directly from the study's public registry record.
Mar Mañú Pereira PhD · +34 93 489 4063 · mar.manu@vhir.org
Always discuss trial participation with your own doctor first.
| Hospital de la Santa Creu i Sant Pau | Barcelona, Barcelona, Spain | Recruiting |
| Hospital Universitari Vall d'Hebron | Barcelona, Barcelona, Spain | Recruiting |
| Hospital Sant Joan de Déu | Esplugues de Llobregat, Barcelona, Spain | Recruiting |
| Hospital General de Granollers | Granollers, Barcelona, Spain | Recruiting |
| Consorci Sanitari del Maresme - Hospital de Mataró | Mataró, Barcelona, Spain | Recruiting |
| Parc Taulí Hospital Universitari | Sabadell, Barcelona, Spain | Recruiting |
| Hospital Universitari Mútua de Terrassa | Terrassa, Barcelona, Spain | Recruiting |
| Consorci Sanitari de Terrassa | Terrassa, Barcelona, Spain | Recruiting |
| Hospital Universitari Arnau de Vilanova | Lleida, Lleida, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07206095